Status:
COMPLETED
A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Anti-biotic Resistance
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the feasibility, safety and efficacy of oral probiotic, VSL#3 versus oral placebo for reducing colonization by VRE.
Detailed Description
Healthcare-associated infections are an important threat to patient safety. Currently, between 5 and 10 percent of patients admitted to acute care hospitals acquire one or more infections; healthcare-...
Eligibility Criteria
Inclusion
- subjects will be male or female
- 18 years of age or older
- may or may not be hospitalized
- able to take oral medications
- have been found to be colonized with VRE or at high risk of being colonized by VRE and are not taking antibiotics
Exclusion
- people on antibiotics will not be eligible to participate
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00933556
Start Date
October 1 2008
End Date
March 1 2012
Last Update
October 8 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of wisconsin hospital
Madison, Wisconsin, United States, 53792